Volume 16, Number 7—July 2010
Dispatch
Vaccine-associated Paralytic Poliomyelitis in Immunodeficient Children, Iran, 1995–2008
Table 1
Age at time of paralysis onset, vaccination history, and characterization of isolated polioviruses, for patients with vaccine-associated paralytic poliomyelitis, Iran, 1995–2008*
Patient no. |
Age, mo/sex at VAPP onset |
OPV, no. doses |
Time intervals | Poliovirus type |
Viral protein 1 nt divergence,† % |
||
---|---|---|---|---|---|---|---|
Last OPV and
VAPP onset |
Virus shedding from VAPP onset |
VAPP onset and death |
|||||
1 | 17/F | 0‡ | 0 | 1.2 mo | 8 d | iVDPV type 2 | 2.2 |
2 | 7/M | 4 | 1.1 mo | 3 mo | 4 mo | iVDPV type 2 | 1.1–1.5 |
3 | 10/M | 4 | 3.3 mo | 2 wk | 1 mo | iVDPV type 2 | 1.7 |
4 | 15/M | 4 | 9 mo | 5 mo | 11 mo | iVDPV type 3 | 2 |
5 | 5/F | 2 | 3.2 mo | 5 d | 1 mo | iVDPV type 2, iVDPV type 1 | Type 2: 1.7–2; type 1: 1.7 |
6 | 20/M | 4 | 1.1 mo | 3 d | NA§ | iVDPV type 2 | 1.2 |
*VAPP, vaccine-associated paralytic poliomyelitis; OPV, oral polio vaccine; iVDPV, immunodeficiency-associated vaccine-derived polioviruses.
†From the prototype Sabin strain.
‡Inactivated polio vaccine was administered. Contact case-patient of a healthy OPV-vaccinated sibling.
§Alive to date, has residual paralysis.